Company · CBIO
Crescent Biopharma, Inc.
Name as listed on its exchange; filed with the SEC as CRESCENT BIOPHARMA, INC.
Nasdaq's symbol directory lists CBIO on Nasdaq as “Crescent Biopharma, Inc. - Common Stock”.
In the 12 months to Nov 8, 2026: insiders bought on 1 occasion ($12.4M); insiders sold on 16 occasions ($1.5M); 4 planned-sale notices; 3 filings by holders of 5% or more; 1 company report (Form 8-K, since May 26, 2026).
Insider trades · SEC Form 4
Those inside the hall
Open-market purchases and sales only. Legs one person filed for one day are combined.
Who traded
- Fairmount Funds Management LLC bought $12.4M
- Brumm Joshua T, Chief Executive Officer sold $921K
- McNeill Jonathan, President and COO sold $447K
- Pinkas Jan, Chief Scientific Officer sold $35K
- Im Ellie Eunkyung, Chief Medical Officer sold $33K
- Bispham Barbara Harlin, General Counsel and Corporate Secretary sold $33K
- Scalzo Richard William, Chief Financial Officer sold $30K
- Lynch Ryan, Treasurer, Senior Vice President of Finance and Chief Accounting Officer sold $13K
Every trade (17)
- SELLBrumm Joshua T, Chief Executive Officer sold $131K
- SELLMcNeill Jonathan, President and COO sold $64K
- SELLBrumm Joshua T, Chief Executive Officer sold $29K
- SELLMcNeill Jonathan, President and COO sold $13K
- SELLPinkas Jan, Chief Scientific Officer sold $12K
- SELLIm Ellie Eunkyung, Chief Medical Officer sold $11K
- SELLBispham Barbara Harlin, General Counsel and Corporate Secretary sold $11K
- SELLScalzo Richard William, Chief Financial Officer sold $10K
- SELLLynch Ryan, Treasurer, Senior Vice President of Finance and Chief Accounting Officer sold $4K
- BUYFairmount Funds Management LLC bought $12.4M
- SELLBrumm Joshua T, Chief Executive Officer sold $761K
- SELLMcNeill Jonathan, President and COO sold $370K
- SELLPinkas Jan, Chief Scientific Officer sold $23K
- SELLIm Ellie Eunkyung, Chief Medical Officer sold $22K
- SELLBispham Barbara Harlin, General Counsel and Corporate Secretary sold $22K
- SELLScalzo Richard William, Chief Financial Officer sold $20K
- SELLLynch Ryan, Treasurer, Senior Vice President of Finance and Chief Accounting Officer sold $8K
Planned sales · SEC Form 144
Notice given
A Form 144 is filed before an insider sells restricted stock. It states an intent; the sale, if it happens, appears later on a Form 4. Every recent notice
- Joshua T Brumm $155K
- Jonathan McNeill $76K
- Joshua T Brumm $33K
- Jonathan McNeill $15K
Large holders · SEC Schedules 13D and 13G
Five percent and over
Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G
- BlackRock, Inc. 5.6%
- BALYASNY ASSET MANAGEMENT L.P. 6.03%
- Fairmount Funds Management LLC 16.5%
Company reports · SEC Form 8-K
In its own words
Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.
- Other events Oct 15, 2026
Sources: SEC EDGAR (Forms 4, 144 and 8-K) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.